APA (7th ed.) Citation

J, D. S., H, N., LA, W., C, A., JA, D., A, F., . . . M, S. (2017). Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder. The Journal of pharmacology and experimental therapeutics, 360(2), 346. https://doi.org/10.1124/jpet.116.237313

Chicago Style (17th ed.) Citation

J, Di Salvo, et al. "Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder." The Journal of Pharmacology and Experimental Therapeutics 360, no. 2 (2017): 346. https://doi.org/10.1124/jpet.116.237313.

MLA (9th ed.) Citation

J, Di Salvo, et al. "Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder." The Journal of Pharmacology and Experimental Therapeutics, vol. 360, no. 2, 2017, p. 346, https://doi.org/10.1124/jpet.116.237313.